63. Fielmann Akademie Kolloquium
1. International Joint Colloquium with the European Academy of Optometry and Optics (EAOO)

Update AMD

Dienstag, 13. November 2024

The Macular Breakdown – Pathophysiology and Management of AMD

Prof. Dr. Marcel N. Menke, Chief Scientific Advisor, ocumeda AG, Riedt bei Erlen, Switzerland; Chief Physician and Clinic Director, Eye Clinic Cantonal Hospital Aarau, Switzerland

Abstract/Summary:

Age-related macular degeneration (AMD) represents a leading cause of irreversible vision loss in older adults, particularly impacting quality of life by compromising central vision. This presentation explores AMD from its foundational principles to advanced management strategies, providing essential knowledge to support patient care.

Introduction and Risk Factors:

The first section introduces AMD, outlining its prevalence and significance within the aging population. Key risk factors are discussed, including age, genetics, lifestyle influences (like smoking), and underlying systemic health conditions. These factors set the stage for understanding AMD as a progressive condition that benefits from early detection and intervention.

Pathophysiology of AMD:

Next, we delve into the cellular mechanisms underlying AMD. We examine the roles of oxidative stress, inflammation, Lipofuscin, macular pigment and the accumulation of drusen, focusing on the degeneration of the retinal pigment epithelium (RPE) and photoreceptor cells in the macula. This section highlights differences in pathophysiology between the two primary forms of AMD: dry (non-exudative) and wet (exudative) AMD.

Types of AMD – Dry vs. Wet:

Understanding the differences between dry and wet AMD is essential for diagnosis and management. Dry AMD, which progresses slowly, is characterized by the accumulation of drusen and gradual macular thinning. In contrast, wet AMD involves neovascularization and faster progression, often leading to more rapid vision loss. This section provides a comparative overview, emphasizing the clinical signs and symptoms that distinguish these types.

Diagnostic Tools:

Effective AMD management begins with accurate diagnosis. This section reviews current diagnostic tools, including optical coherence tomography (OCT), fundus photography, and fluorescein angiography and fundus autofluorescence imaging. Special emphasis is placed on OCT's role in detecting structural changes in the retina and monitoring disease progression.

Treatment and Management:

Moving to therapeutic approaches, this section covers current treatments and emerging therapies. For dry AMD, lifestyle interventions, dietary supplements, and patient education form the backbone of care, with a focus on delaying progression. For wet AMD, anti-VEGF injections, laser therapy, and photodynamic therapy are highlighted as treatment options.

Prevention Strategies:

Beyond treatment, prevention strategies play a crucial role in AMD management. We explore evidence-based lifestyle modifications, including diet adjustments (rich in antioxidants, zinc, and omega-3 fatty acids) and smoking cessation, aiming to educate patients on minimizing their risk factors.

Conclusion and Takeaways:

The presentation concludes with key takeaways and practical tips for practitioners, summarizing AMD's impact, diagnostic strategies, and management approaches. The goal is to equip care provider with a holistic understanding of AMD, enhancing their ability support patients facing this complex condition.

Diagnosing AMD – Can AI do the job?

Univ.-Prof. Dr. Ursula Schmidt-Erfurth, MD Head of Department of Ophthalmology and Optometry; Medical University of Vienna, Austria; Director of OPTIMA Ophthalmic Image Analysis Laboratory

Age-related macular degeneration (AMD) represents one of the most pressing challenges in ophthalmology, being the leading cause of persistent vision impairment worldwide. With an aging global population, the prevalence of AMD is expected to increase significantly, intensifying the need for improved diagnostic and management strategies. Despite advances in imaging technologies, such as optical coherence tomography (OCT), traditional diagnostic approaches face limitations due to delayed detection, subjective variability in manual interpretation, and limited accessibility to expert care. These challenges underscore the critical need for integrating artificial intelligence (AI) into the diagnostic and therapeutic workflows for AMD.

Recent developments in AI have demonstrated profound potential in addressing these issues, particularly in analyzing high-resolution imaging data. AI algorithms, leveraging deep learning techniques, can process and evaluate large datasets with remarkable speed and precision, outperforming human capabilities in several key areas such as therapeutic monitoring and diagnostic screening. Among the most notable innovations and the first to be approved for clinical use is the "Fluid Monitor," an AI-driven software specifically designed to analyze OCT images. This tool distinguishes between intraretinal, subretinal, and sub-retinal pigment epithelium (sub-RPE) fluid accumulations at pixel-level accuracy. These distinctions are crucial for guiding treatment decisions in managing neovascular AMD. For instance, intraretinal fluid urgently necessitates intravitreal injections of anti-VEGF agents, whereas subretinal fluid has been associated with protective effects on photoreceptor functionality and may not require immediate intervention, if stable. The Fluid Monitor's color-coded and en face visualization and accurate volume quantification provides clinicians with clear, actionable insights, reducing diagnostic variability and enhancing treatment precision.

The HORIZON I-Screen project exemplifies the practical application of AI in screening and preventive eye care. This initiative emphasizes collaboration between ophthalmologists and optometrists to combine AI-based tools with community-based screening programs to improve early detection rates in neovascular and atrophic AMD "next door" by opticians/optometrists seeing the majority of individuals above the age of 50 years. By leveraging high-resolution imaging devices and cloud-based AI platforms, the project offers remote, i.e. cloud-based, real-time analysis of retinal images, enabling timely referral and inter-

vention. This approach not only enhances accessibility, but also provides valuable epidemiological data to inform public health strategies.

Moreover, due to its diagnostic accuracy and consistency, AI is not only faster, but also more reliable and reproducible with DICE scores of 0.9. In contrast, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) highlighted a diagnostic concordance of only 72% among experienced ophthalmologists, underscoring the subjective nature of manual evaluations. AI systems offer objective and reproducible results, significantly reducing the likelihood of diagnostic errors. This capability is particularly valuable in high capacity clinics, saving time and manpower, while improving quality. By enabling rapid and reliable image interpretation, AI tools can democratize eye care, making advanced diagnostics accessible to a broader population, including at-risk groups. Beyond its diagnostic applications, AI is poised to transform patient management. Continuous tracking of disease progression through automated analysis of longitudinal imaging data allows for highly personalized treatment regimens. This approach minimizes the risk of undertreatment, a common concern with anti-VEGF therapies, ensuring adequate interventions when disease activity is detected. The integration of AI into clinical practice not only enhances efficiency, but also aligns with the principles of evidence-based medicine, providing data-driven insights optimize patient outcomes.

AI in ophthalmology has already overcome several challenges: One significant barrier has been the need for robust and diverse training datasets to ensure the generalizability of AI algorithms across different patient populations. Ethical considerations, including data privacy and the transparency of AI decision-making processes, also warrant careful attention. Moreover, the successful implementation of AI requires interdisciplinary collaboration among clinicians, data scientists, and policymakers to address regulatory and infrastructural hurdles. MDR class 2 certification and compliance with ISO norms for the Fluid Monitor in neovascular AMD and the GA Monitor (RetInSight, Vienna, Austria) for atrophic AMD cover such challenges adequately.

In conclusion, the role of AI in AMD diagnostics and management is not merely supportive, but transformative. Tools like the Fluid/GA Monitor and initiatives such as the HORIZON I-Screen project exemplify the potential of AI to enhance diagnostic accuracy, efficiency, and accessibility, representing a paradigm shift in ophthalmology and shared care. As the field continues to evolve, fostering interdisciplinary partnerships and addressing implementation challenges will be pivotal in realizing the full potential of AI. By bridging the gap between advanced technology and clinical practice, AI has the potential to mitigate the growing burden of AMD and improve the quality of life for millions of individuals worldwide. AI has already provided proof-of-principle to be able to "do the job", it is now in the hands of eyecare professionals to make it work anywhere and any time.

Effective Strategies for Safely Managing Patients with AMD – current approaches in Low Vision

Frank Wersich, Master Optician and Optometrist (HWK); Managing Director of Schrodin & Wersich Optik GmbH, Baden Baden, Germany

Age-related macular degeneration (AMD) poses a growing challenge, particularly in light of demographic shifts. Studies indicate that the number of individuals affected by AMD will rise significantly in the coming years. This trend necessitates new approaches in low-vision care, incorporating technological aids as well as emotional and individualized support. There are six key strategies for effectively managing patients with AMD summarized below.

Demographic Shifts and Their Impacts

Demographic shifts are leading to an increase in the aging population, resulting in a growing group of AMD patients. Data show that the number of people with severe visual impairments in Germany increased from 5.7 million in 2002 to 7.0 million in 2017. This trend is expected to continue until 2035, necessitating adjustments in low-vision care:

- Greater specialization in AMD patient care.
- Increased number of professionals in vision rehabilitation.
- Expansion of the market for assistive devices to meet rising demand.

Key Insight: *Demographic shifts fundamentally alter the requirements for AMD patient care.*

Understanding the Condition and Patient Education

Clear and empathetic communication about the condition is essential for building trust. Patients should not only be informed about the various forms of AMD, their symptoms, and the impact on vision but also feel that the low-vision specialist deeply understands their unique situation. The following approaches foster this trust:

- **Explaining the Diagnosis Empathetically:** In addition to clear language and illustrative examples, such as the Amsler grid, it is crucial to give patients space to voice their concerns and fears. Low-vision specialists should actively listen and convey understanding.
- **Setting Realistic Expectations:** Patients should be honestly informed about the possibilities and limitations of treatment, always accompanied by a positive and supportive attitude.
- **Demonstrating Empathy:** Understanding the emotional burden of patients is crucial. Knowing that their challenges are taken seriously provides patients with reassurance.
- **Involving Family Members:** Relatives should not only be informed but also actively involved in

the care process to provide comprehensive support.

A low-vision specialist must position themselves as a trusted companion who imparts not only technical expertise but also warmth and understanding.

Key Insight: *Effective communication, empathy, and a deep understanding of the condition build trust and lay the foundation for successful therapy.*

Use of Assistive Devices

There is a wide range of assistive devices that must be tailored to the needs of each patient. These aids can be categorized as follows:

- **Optical Aids:** Magnifiers, special reading glasses, and filter lenses.
- **Non-Optical Aids:** Lighting aids, large print materials, and tactile books.
- **Electronic Aids:** Video magnifiers, tablets, and voice-controlled devices.
- **Auditory Aids:** Audiobooks and talking devices.
- **Mobility Aids:** White canes and electronic mobility aids.

Further emphasized the importance of continually integrating new technologies into patient care. Future developments, such as advanced AI-driven vision devices and enhanced electronic readers, could significantly improve patients' quality of life.

Key Insight: *A combination of various assistive devices tailored to individual needs is key to success.*

Individualized Care and Adaptation to the Environment

Personalized care and training for daily life are essential. Rehabilitation plays a central role in this process. The goal is to equip patients with skills to maintain or regain their independence. Examples of effective rehabilitation measures include:

- **Orientation Training:** Patients learn to navigate safely in their daily lives using mobility aids such as white canes or electronic devices.
- **Training with Assistive Devices:** Focused training on the use of magnifiers or electronic readers to facilitate reading and object recognition.
- **Household Adjustments:** Improving lighting, marking household items, or using high-contrast materials to make everyday tasks more accessible.
- **Technology Integration:** Introducing patients to the use of voice assistants or apps designed specifically for visually impaired individuals.
- **Psychosocial Training:** Supporting patients in adapting to new life circumstances and overcoming challenges in daily life.

Rehabilitation should be tailored to the individual needs of the patient to achieve the best possible outcomes.

Key Insight: *Individualized care, particularly through specialized rehabilitation, empowers patients to strengthen their independence and lead fulfilling lives.*

Emotional Support

An AMD diagnosis can be emotionally challenging for patients. Providing psychological support is crucial to:

- Help patients cope with shock, anger, and grief.
- Foster acceptance of the diagnosis and adaptation to new life realities.
- Promote long-term well-being and personal growth.

Key Insight: *Emotional support is a central component of AMD care.*

Regular Monitoring and Adjustment

Continuous care is often underestimated, yet it holds significant potential. Regular check-ups ensure that assistive devices and strategies continue to meet patients' evolving needs. This stage often reveals new requirements that can be addressed with additional assistive solutions. This creates added value for the patient while presenting an opportunity for businesses to generate additional revenue.

For instance, after successfully equipping a patient with an initial set of devices and ensuring proper use, new needs may arise that can be met with advanced tools or upgrades. In the optical industry, routine follow-ups for glasses, contact lenses, or eye tests are common practice. Applying this approach to AMD patients by proactively offering updates or evaluations can enhance their quality of life while creating sustained business growth.

Key Insight: *Continuity, adaptability, and proactive engagement ensure both therapeutic success and business opportunities.*

Conclusion

Caring for AMD patients requires a comprehensive, multidisciplinary approach. By combining technical support, individualized care, and emotional assistance, patients can be optimally supported in their daily lives. Furthermore, the positive impact on accompanying persons should not be underestimated. These individuals often recognize the expertise of the low-vision specialist, which fosters trust in their competence and may motivate them to address their own vision needs, such as glasses or contact lenses. Additionally, the growing demand for specialized care presents a promising business opportunity. Companies can establish a new market position through innovative approaches and professional care, benefiting from increased demand in the long term. This not only offers economic prospects but also the chance to sustainably improve the lives of many people.